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Abstract 
Permanent neonatal diabetes is caused by reduced β-cell number or impaired β-cell function. 
Understanding the genetic basis of this disorder highlights fundamental β-cell mechanisms.  
We performed trio genome sequencing for 44 permanent neonatal diabetes patients and their 
unaffected parents to identify causative de novo variants. Replication studies were performed in 188 
patients diagnosed with diabetes before 2 years of age without a genetic diagnosis. 
EIF2B1 (encoding the eIF2B complex α subunit) was the only gene with novel de novo variants (all 
missense) in at least three patients. Replication studies identified 2 further patients with de novo 
EIF2B1 variants. In addition to diabetes, 4/5 patients had hepatitis-like episodes in childhood. The 
EIF2B1 de novo mutations were found to map to the same protein surface. We propose that these 
variants render the eIF2B complex insensitive to eIF2 phosphorylation which occurs under stress 
conditions and triggers expression of stress-response genes. Failure of eIF2B to sense eIF2 
phosphorylation likely leads to unregulated unfolded protein response and cell death.  
Our results establish de novo EIF2B1 mutations as a novel cause of permanent diabetes and liver 
dysfunction. These findings confirm the importance of cell stress regulation for β-cells and highlight 
EIF2B1’s fundamental role within this pathway. 
  
Introduction 
Permanent neonatal diabetes (PNDM) is a genetically and clinically heterogeneous condition 
diagnosed before the age of 6 months. A genetic cause is identified in 82% of cases, resulting in 
improved treatment in almost 40% (1).  
Thirty-nine percent of patients with PNDM have a genetic aetiology resulting in development of at 
least one extra-pancreatic feature, alongside diabetes (1). The most common PNDM syndromic 
subtype is Wolcott-Rallison syndrome, which is caused by autosomal recessive mutations in the 
EIF2AK3 gene. Individuals with Wolcott-Rallison syndrome usually develop diabetes in the first year 
of life. They also present with repeated episodes of hepatitis-like liver dysfunction, which eventually 
results in fatal liver failure, and skeletal dysplasia. The EIF2AK3 mutations in these patients are 
thought to result in disruption of the unfolded protein response (UPR) and cell death due to 
unregulated endoplasmic reticulum (ER) stress (2; 3). Approximately 15% of individuals with 
syndromic PNDM do not have a mutation in one of the known causative genes, suggesting the 
existence of novel genetic subtypes (4). 
Identifying novel genetic causes of PNDM is crucially important to gain insights into human β-cell 
development, function and survival and could identify potential targets for novel therapies.  
We used a trio-based genome sequencing approach to identify heterozygous de novo EIF2B1 
mutations as the cause of a novel genetic syndrome characterised by permanent neonatal/early onset 
diabetes and transient liver dysfunction.  
  
Methods 
Subjects.  
Individuals with PNDM and early onset diabetes were recruited by their clinicians for genetic analysis 
in the Exeter Molecular Genetics Laboratory. The study was conducted in accordance with the 
Declaration of Helsinki, and all subjects or their parents gave informed consent for genetic testing.  
Genome sequencing.  
Genome sequencing was performed on DNA extracted from peripheral blood leukocytes of 44 
probands diagnosed with PNDM before the age of 6 months and their unaffected, unrelated parents. 
Samples were sequenced on an Illumina HiSeq2500 with a mean read depth of 30. The sequencing 
data was analysed using an approach based on the GATK best practice guidelines. Briefly, the reads 
were aligned to the hg19/GRCh37 human reference genome with BWA mem, Picard used for 
duplicates removal, and GATK IndelRealigner for local re-alignment. GATK haplotypecaller was 
used to identify variants which were annotated using Alamut batch v1.8 (Interactive Biosoftware, 
Rouen, France). Variants which failed the QD2 VCF filter or had < 5 reads supporting the variant 
were excluded. CNVs were called by SavvyCNV (5) which uses read depth to predict copy number.  
Targeted next generation sequencing. Replication studies were performed in a cohort of 188 
patients diagnosed with diabetes before 2 years of age in whom the 25 known genetic causes of 
neonatal diabetes had been excluded. Patients were analysed using a targeted next generation 
sequencing assay, including the known monogenic diabetes genes and additional candidate genes, 
such as EIF2B1 (NM_001414.3). Variant confirmation and co-segregation in family members was 
performed by Sanger sequencing. 
Sanger sequencing confirmation. EIF2B1 exon 3 (NM_001414.3) was amplified using in-house 
designed primers (F – TGTTCACTGATGTATCCCTAGCA, R – 
TCCTAGGAAGAAAAGAGCAAACT). PCR products were sequenced on an ABI3730 capillary 
machine (Applied Biosystems) and analysed using Mutation Surveyor v3.98 (SoftGenetics). The 
bioinformatics tools SIFT, PolyPhen-2 and Align GVGD were accessed through the Alamut Visual 
software (Interactive Biosoftware) to predict the effect of the variants.  
Variants are reported using the HGVS nomenclature guidelines (6). 
Molecular modelling of the EIF2B1 stop-loss variant. The predicted structure of the EIF2B1 stop-
loss variant, c.915_916del, p.(*306Thrext*12) was modelled using the Phyre2 web server in intensive 
mode 3, with the full-length sequence of variant eIF2Bα as input. The resulting structure was 
modelled entirely on PDB entry 3ecs (crystal structure of human eIF2Bα 4) except for the C-terminal 
extension which was modelled ab initio. All structures were visualized in PyMOL ( Molecular 
Graphics System v2.0, Schrödinger LLC). 
Data and resource availability. EIF2B1 mutation details have been deposited in the Decipher 
database (https://decipher.sanger.ac.uk/). All other data sets generated and/or analysed for this study 
are available from the corresponding author upon reasonable request. 
 
  
Results 
Genetic analysis 
EIF2B1 was the only gene identified with de novo variants in at least three patients. The three 
missense EIF2B1 variants identified, p.(Gly44Asp), p.(Gly44Val), and p.(Ser77Asn) (Table 1), were 
not listed in the gnomAD database (7) and affected residues which are highly conserved across 
species (up to Zebrafish for p.Gly44, up to Chicken for p.Ser77). No deletions or duplications 
involving EIF2B1 were detected. 
Sequencing of EIF2B1 in 188 further patients without a known genetic diagnosis who had developed 
diabetes before the age of two years identified two additional novel heterozygous EIF2B1 variants, 
p.(Leu34Trp) and p.(*306Thrext*12). Parental testing showed that both variants had arisen de novo. 
Clinical features 
The clinical features of the 5 subjects with de novo EIF2B1 mutations are summarised in Table 1. All 
had been diagnosed with permanent diabetes between the age of 4 and 56 weeks and were treated with 
full replacement insulin doses (range 0.46-1 U/kg/day). All 4 patients for whom data was available 
had low birth weight (< 20
th
 centile, SDS range -0.84 - -1.74) consistent with reduced insulin secretion 
in utero. 
Four of the five patients had suffered episodes of hepatic dysfunction in childhood with hepatitis-like 
derangement of liver enzymes. The severity of these episodes was variable: in case 3 the first episode 
resulted in fatal acute liver failure, whilst in the other three cases it resolved with return to normal 
liver function and enzymes. Case 1 presented once with elevated liver enzymes at the age of 38 
months. Cases 4 and 5 experienced multiple episodes requiring hospitalisation between the ages of 5 
months and 5.5 years but have not experienced any further episodes (current ages 13 and 18).  
No severe neurological features were reported, however Case 4 has mild learning disability and Case 
5 has attention deficit disorder. 
In silico protein analysis 
EIF2B1 encodes for the α subunit of the heterodecameric eIF2B complex, which modulates the 
activity of the Eukaryotic Translation Initiation Factor 2 (eIF2) to regulate translation initiation and 
protein synthesis in basal and stress cell conditions. Under cell stress, serine 51 of eIF2α is 
phosphorylated by kinases of the Integrated Stress Response (ISR) (8). This phosphorylation results in 
altered interaction with eIF2B to inhibit the rate of translation of most mRNAs, with the exception of 
stress-response genes RNAs which are able to circumvent this block to allow cell recovery (9; 10). 
The recent publication of the structures of human eIF2B in complex with both phosphorylated and 
non-phosphorylated eIF2 (11; 12) showed that in its non-phosphorylated form, eIF2α makes contact 
with the eIF2B β,  and  subunits, but not with eIF2Bα. However, upon Ser51 phosphorylation, 
eIF2α binds tightly to eIF2Bα, resulting in a markedly different orientation of eIF2 in the complex 
with eIF2B (Figure 1A).  
Mapping the heterozygous EIF2B1 variants from our 5 cases shows that these all lie at the same 
surface as that occupied by phosphorylated eIF2α (Figure 1B). Moreover, one of these variants 
(identified in Case 3) occurs at p.Ser77 of eIF2Bα, which makes both hydrogen-bonded and non-
bonded contacts with residues of phosphorylated eIF2α. In the stop-loss variant identified in Case 5, 
the C-terminal extension to eIF2Bα is likely to sterically hinder the interaction of eIF2α with eIF2Bα 
p.Leu305 as well as possibly occluding other parts of the interface (Figure 1C).  
  
Discussion 
We report the identification of EIF2B1 heterozygous de novo variants in 5 patients with permanent 
neonatal/early onset diabetes and transient liver dysfunction. The variants, 4 missense and one stop-
loss, are all predicted to map to the same protein surface and in silico modelling suggests that they are 
likely to disrupt the interaction of the EIF2Bα subunit (encoded by EIF2B1) with phosphorylated 
EIF2α during the cell ISR. 
Our patients’ clinical features are markedly different from those reported in patients with 
leukoencephalopathy with vanishing white matter (VWM), a rare paediatric neurological disease 
caused by recessive loss of function EIF2B1 mutations (13). VWM is a progressive condition, usually 
fatal in childhood. Extra-neurological features are generally not present, although diabetic 
ketoacidosis at 8 months was reported in one patient with a homozygous p.(Leu49Arg) variant in 
EIF2B1 (14). None of the five patients we report had severe neurological features, however Case 4 
has mild learning disability and Case 5 has attention deficit disorder. The parents of individuals with 
VWM, who are heterozygous carriers for EIF2B1 loss of function mutations, are unaffected, thereby 
supporting our hypothesis that the mutations identified in our patients do not result in complete loss of 
function of the eIF2B complex. 
eIF2B regulates translation initiation and protein synthesis by modulating eIF2activity. During protein 
synthesis under normal conditions, eIF2B acts to recycle initiation factor eIF2 for further rounds of 
translation by promoting its dissociation from GDP, allowing replacement by GTP and subsequent 
association of GTP-bound eIF2 with the initiator methionyl-tRNA. Under stress condition, specific 
kinases phosphorylate the serine 51 of eIF2α (8) resulting in inhibition of GDP dissociation, 
attenuating recycling of eIF2 to its active GTP-bound form through altered interaction with eIF2B and 
consequently inhibiting the rate of translation of most mRNAs (9; 10) (Figure 2A).  
Mapping the heterozygous EIF2B1 variants identified in the 5 cases we report shows that these all 
localise at the same surface as that occupied by phosphorylated eIF2α (Figure 1B). Moreover one 
variant, p.(Ser77Asn), identified in Case 3 occurs at a residue which directly interacts with 
phosphorylated eIF2α. Two mutations, identified in cases 1 and 2, involve eIF2Bα p.Gly44. Previous 
experiments have shown that mutation of the equivalent residue in GCN3, the yeast orthologue of 
EIF2B1, results in full cell viability under normal conditions but failure to respond to eIF2α 
phosphorylation under stress (15). In contrast, most EIF2B1 variants which have been reported in 
patients with VWM occur at interfaces with other eIF2B subunits (Figure 1D), consistent with their 
reported effects on the formation and/or stability of the eIF2B complex (16). Taken together, this 
evidence strongly suggests that the EIF2B1 variants identified in our patients are likely to result in 
formation of the eIF2B complex and support translation under normal conditions, but impair eIF2B 
binding to phosphorylated eIF2α under stress conditions. 
Impaired cellular stress response is a known β-cell dysfunction mechanism and is involved in other 
genetic subtypes of PNDM, including Wolcott-Rallison syndrome, the most common syndromic form 
of the disease (17). Wolcott-Rallison syndrome is characterised by permanent neonatal/early onset 
diabetes, severe liver dysfunction (presenting with transient episodes of acute liver failure) and 
skeletal dysplasia, and is caused by recessive mutations in the EIF2AK3 gene, encoding the Pancreatic 
eIF2-alpha kinase (PERK) (18). EIF2AK3 loss of function variants in Wolcott-Rallison syndrome 
disrupt the ISR thereby limiting the response to ER stress, impairing the cell’s ability to recover and 
leading to cell death (Figure 2B).  
Our results are consistent with the hypothesis that the EIF2AK3 variants in Wolcott-Rallison 
syndrome and the novel EIF2B1 variants identified in our cases affect different steps within the same 
ER stress response pathway (Figure 2C), highlighting the importance of this pathway in pancreatic β 
and liver cell function and integrity (19). The convergence of both EIF2B1 and EIF2AK3 on the ISR 
provides an explanation for the phenotypic overlap between Wolcott-Rallison syndrome and the 
disease caused by dominant EIF2B1 variants, consisting of neonatal/early onset diabetes and liver 
dysfunction. However, whereas liver symptoms appear to resolve with age in the patients with 
EIF2B1 variants, prognosis in Wolcott-Rallison syndrome is poor and most patients die of liver 
failure. Additionally, individuals with Wolcott-Rallison syndrome have skeletal dysplasia, a feature 
not observed in the cases with EIF2B1 variants we report. It has been proposed that the skeletal 
manifestations in Wolcott-Rallison syndrome arise specifically from a developmental defect in 
osteoblasts due to absence of PERK activity (2; 3) rather than from the ER stress regulation defect 
which is thought to cause PNDM and liver failure. Another possible explanation for the differences in 
the extra-pancreatic phenotypes in cases with Wolcott-Rallison syndrome and the individuals with 
EIF2B1 de novo variants we report could be the existence of quantitative differences in strength of 
signal or in its specific relationship to ER stress. It is possible that the level of attenuation of the ISR 
and the context for the attenuation caused by heterozygous mutations in EIF2B1 are enough to cause 
β-cell dysfunction and diabetes, but not enough to result in the severe liver and skeletal phenotype.  
In summary, we report a novel genetic syndrome of neonatal/early onset diabetes and transient liver 
dysfunction caused by dominant de novo EIF2B1 mutations which disrupt the ability of the eIF2B 
complex to sense eIF2 phosphorylation, and likely result in severe ER stress. These results further 
highlight the importance of ER stress regulation for β-cell function, adding another key gene to the list 
of ER stress regulators which, when mutated, cause syndromic forms of diabetes (4; 20-27). This 
knowledge is crucial to inform current efforts aimed at developing targeted therapies for patients with 
syndromic forms of diabetes caused by ER stress dysregulation (28; 29) but also for patients with type 
2 (30) and type 1 diabetes (31), as ER stress is known to play a key role in the pathogenesis of these 
more common diabetes subtypes. 
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Table 1: Patients’ clinical features 
Case # 1 2 3 4 5 
Mutation 
c.131G>A 
p.(Gly44Asp) 
c.131G>T 
p.(Gly44Val) 
c.230G>A 
p.(Ser77Asn) 
c.101T>G 
p.(Leu34Trp) 
c.915_916del, 
p.(*306Thrext*12) 
De novo Yes Yes Yes Yes Yes 
Sex Male Male Female Male Male 
Current age 
(years) 
5 5 Deceased 13 18 
Country Vietnam Jordan Chile England Israel 
Birth Weight (g) 2600 3000 2986 2920 3600 
Gestation (weeks) 39 N/A 40 40 42 
Birth weight 
centile  (SDS) 
4
th
 (-1.74) N/A 18
th
 (-0.90)  7
th
 (-1.44) 20
th
 (-0.84) 
Diabetes features 
Age at onset 
(weeks) 
9 4 17 56 21 
Insulin treatment 
from 
diagnosis, 
0.46U/kg/day 
(at 2 months) 
from diagnosis, 
0.8U/kg/day 
 from diagnosis, 
1.0U/kg/day 
from 
 diagnosis, 
0.7U/kg/day 
from  
diagnosis, 
0.75U/kg/day 
Hepatic features 
Age at first 
episode of liver 
dysfunction 
38 months None reported 16 months  18 months 5 months 
Outcome of first 
episode 
Resolved  N/A Decease  Resolved Resolved 
Recurrent 
episodes 
No  N/A  N/A Yes, 8 episodes Yes, 2 episodes 
Age at last 
episode of liver 
dysfunction 
 N/A  N/A  N/A 5.5 years 5.5 months  
Other features 
Neurological 
features 
None None None 
Mild learning 
disability  
Attention deficit 
disorder 
Additional 
Comments 
Anaemia   
 Died at 16 
months 
following 
respiratory 
infection and 
acute liver 
failure 
Renal failure at 
14 years 
  
 
  
Figure legends 
Figure 1: Heterozygous EIF2B1 variants in neonatal diabetes lie in the binding surface for 
phosphorylated eIF2α. A) Structure of human eIF2B in complex with phosphorylated eIF2α (Ser51-
P) (PDB id 6o9z (12)); the eIF2B complex is a heterodecamer comprised of two molecules each of 
subunits α, β, ,  and ε. B) As A, but shown without eIF2α (Ser51-P); positions of heterozygous 
missense variants in eIF2Bα identified in neonatal diabetes patients are coloured red and labelled in 
black font; the position of the homozygous p.(Leu49Arg) variant reported in a VWM patient is 
coloured orange and labelled in blue font; Leu305 (grey) is the C-terminal residue of eIF2Bα. C) The 
stop-loss variant c.915_916del, p.(*306Thrext*12) is expected to result in the addition of 12 novel 
amino acids (Thr-Cys-Glu-Pro-Phe-Pro-Ala-Lys-Val-Gln-Leu-Thr) to the C-terminal of eIF2B; this 
C-terminal extension (dark red) was predicted to form a short helix extending from Leu305 lying 
across the surface bound by eIF2α[Ser51-P]. D) As A, but zoomed and showing selected subunits 
(eIF2α[Ser51-P]; eIF2B subunits β,  and α’) in ribbon format; surface positions of heterozygous 
missense variants identified in neonatal diabetes patients are coloured red, and the position of the 
homozygous p.(Leu49Arg) VWM variant orange, as in part B; positions of other homozygous 
variants identified in VWM patients are coloured yellow and labelled in blue font (Tyr275, the site of 
the p.Tyr275Cys variant, is not visible in these views but is surface-accessible at the junction of the 
interfaces with subunits  and α’; Asn208, which was substituted by glutamate in a case of VWM, is 
not accessible at the eIF2Bα surface). The light green residue in the eIF2α ribbon indicates the 
position of phosphoserine 51. 
 
Figure 2: Different forms of monogenic neonatal diabetes affect steps in the Integrated Stress 
Response pathway. A) Stress conditions induce activation of four kinases of the Integrated Stress 
Response (ISR); Pancreatic eIF2-alpha kinase (PERK) responds mainly to ER stress, and is of 
particular importance in maintaining liver and pancreatic β-cells; other kinases of the IRS are Protein 
kinase (PK) R, GCN2 and Heme‐regulated eIF2α kinase (HRI), which respond to dsRNA, amino acid 
deprivation and heme deprivation respectively. Phosphorylation of Ser51 of eIF2α results in a tight 
interaction with eIF2Bα, which inhibits the GDP dissociation activity mediated primarily by the  and 
ε subunits of eIF2B and thus arrests translation of most mRNAs, except for specific mRNAs 
associated with the stress response programme. B) In Walcott-Rallison syndrome, homozygous or 
compound heterozygous loss of function variants in EIF2AK3, the gene encoding PERK, prevent 
phosphorylation of eIF2α Ser51 in response to ER stress; the lack of an appropriate stress response 
ultimately leads to a prolonged unfolded protein response and cell death. C) The dominant eIF2B1 
variants identified in neonatal patients all lie in the binding surface for phosphorylated eIF2α and 
likely prevent effective sensing of Ser51 phosphorylation by eIF2B. This defect would be expected to 
affect the response to all kinases of the ISR, potentially explaining differences in the phenotype 
compared to that of Wolcott Rallison syndrome and the dominant nature of the disease. 
 
